A-Shine s.r.o.

Plzen 3 39 trials 16 recruiting

39 Registered trials

16 Currently recruiting

Organisation

A-Shine s.r.o.

Location

Plzen 3, Czechia

Identifier

ORG-100044111

Address

Sumavska 2, Vychodni Predmesti, 301 00, Czechia

Departments

A-Shine s.r.o
A-SHINE s.r.o.
A-Shine, s.r.o.
N.A
N/A
NA
Neurologie
Oddeleni psychiatrie
Private practice
Psychiatrická ambulance
Psychiatrie
Psychiatry

Clinical trials at this site (39)

Search interface

Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND) Pending

2024-516805-22-00 Major Depressive Disorder 5
Open-label Extension of KarXT + KarX-EC for Agitation in Alzheimer’s Disease Pending

2024-519994-20-00 Agitation Associated with Alzheimer’s Disease 5
Evenamide in patients with treatment-resistant schizophrenia not responding to antipsychotics Recruiting

2024-519836-18-00 treatment-resistant schizophrenia (TRS) 5 2025-12-16
A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer’s Disease Recruiting

2025-520746-30-00 Mild to moderate Alzheimer’s Disease 5 2025-11-18
Long-term study to assess the safety and tolerability of adjunctive NBI-1065845 in adults with Major Depressive Disorder (MDD) Recruiting

2024-519423-24-00 Major Depressive Disorder 5 2025-10-07
A Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Monotherapy Study of the Efficacy, Safety, and Tolerability of SPT-300 in Ad… Recruiting

2025-521240-37-00 Major Depressive Disorder (MDD), with or without Anxiou 4 2025-09-11
An Open label, Safety Clinical trial of (+)-α-dihydrotetrabenazine in patients with moderate to severe tardive dyskinesia Recruiting

2023-509518-12-01 Tardive dyskinesia 4 2024-04-16
Randomised, double-blind, placebo-controlled study to assess safety and efficacy of PRI-002 in patients with MCI or mild dementia due to Alz… Recruiting

2022-503148-41-00 Alzheimer's disease 4 2023-12-01
Clinical trial of (+)-α-dihydrotetrabenazine in patients with moderate to severe tardive dyskinesia with open-label Part I and randomized, d… Recruiting

2024-516852-17-00 Tardive dyskinesia 4 2023-11-13
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated with Alzheimer’s Disease. Recruiting

2025-520612-34-00 Agitation Associated with Alzheimer’s Disease 5 2025-11-28
A 6-Week, Multicenter, Open-Label, Monotherapy, Extension Study of SPT-300 in Adults with Major Depressive Disorder, With or Without Anxious… Recruiting

2025-522347-18-00 Major Depressive Disorder (MDD), with or without Anxiou 4 2025-11-26
A study to assess the efficacy and safety of ITI-1284 as adjunctive treatment in patients with Generalized Anxiety Disorder Recruiting

2024-513302-56-00 Generalized Anxiety Disorder 4 2025-11-17
A Phase 3 Trial to Assess CYB003 in Major Depressive Disorder Recruiting

2024-519270-40-00 Major Depressive Disorder 5 2025-10-30
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder Recruiting

2024-520333-68-00 Major Depressive Disorder 5 2025-09-26
Study to assess the efficacy and safety of adjunctive NBI-1065845 in adults with Major Depressive Disorder (MDD) Recruiting

2024-519418-29-00 Major Depressive Disorder 5 2025-09-19
A study to assess the efficacy and safety of ITI-1284 as monotherapy treatment in patients with Generalized Anxiety Disorder Recruiting

2024-516684-82-00 Generalized Anxiety Disorder 4 2025-07-21
A study to measure how well seltorexant works in adult depressed patients and how safe it is both for short- and long-term use when taken wi… Recruiting

2023-509070-36-00 Major Depressive Disorder with Insomnia Symptoms 5 2025-03-18
A study to see how well KarXT is tolerated and how well tolerated it is when taken for long time in participants with psychosis associated w… Recruiting

2023-504151-27-00 Psychosis associated with Alzheimer’s Disease 5 2024-05-09
A Phase 3, Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Gen… Ended

2024-513572-17-00 Generalized Anxiety Disorder (GAD) 5 2025-08-20
A study to assess the efficacy and safety of ITI-1284 in the treatment of Agitation Associated with Alzheimer's Dementia Ended

2024-514680-26-00 Agitation Associated with Alzheimer’s Dementia 4 2025-07-17
A Study to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Preventive Treatment of Menstrual Migraine Ended

2024-512946-41-00 Menstrual Migraine 5 2025-03-05
Long-term Study to Assess the Safety and Effectiveness of NMRA-335140 in Participants with Major Depressive Disorder Ended

2023-505892-56-00 Major Depressive Disorder 5 2024-09-30
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Oral NMRA-335140 versus Placebo in Participants wit… Ended

2023-506335-15-00 Major Depressive Disorder 5 2024-07-18
A Phase 3 Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants with Early Alzhei… Ended

2023-508306-15-00 Alzheimer’s Disease 5 2024-06-26